Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results – – Ended 2025 with ...

Peer-reviewed publication in “The Oncologist” is now available onlineInvestigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day ...

A live webcast of the presentation will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said members of its management team will present and hold one-on-one meetings at ...

Severe sepsis from bacterial or viral infections can be life-threatening and even people recovering from severe sepsis may experience long-lasting effects on the immune system, making them more ...

ABSTRACT: Background: Diabetic foot ulcer (DFU) is one of the serious complications of diabetes mellitus, with high morbidity and mortality. A plethora of management types are available to treat, and ...

The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...

Objective: To investigate the clinical implications of Golgi glycoprotein 73 (GP73) and granulocyte colony-stimulating factor (G-CSF) in children with bronchopneumonia (BP). Methods: Seventy-two ...

We undertook a therapeutic interchange program, substituting sargramostim for filgrastim for patients undergoing treatment with myelosuppressive chemotherapy. A thorough review of the clinical data ...